Company / Revenue per Share
Protalix BioTherapeutics, Inc. Revenue per Share History
FY2015-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Revenue per Share
$0.86
FY2025
5-year range
$0.65 / $1.57
FY2021-FY2025
Trend
+32.2%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Revenue per Share returned to growth in FY2025 after 4 years of decline, reaching $0.86.
Based on SEC 10-K filings.
0.86 in FY2025 with a 5-year CAGR of -17.8%.
Improved from $0.71 to $0.86 over the past 2 years.
Revenue per Share over time
Growth rates
- 3-Year CAGR
- -14.5%
- 5-Year CAGR
- -17.8%
- 10-Year CAGR
- -
Key checks
Key Insights
- In FY2025, revenue per share increased 32.2% year-over-year.
- Peak revenue per share was recorded in FY2020.
- Lowest revenue per share in the period was in FY2015.
Company context
Key Data Points
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Revenue per ShareValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $0.86 | +32.2% |
| FY2024 | $0.65 | -8.4% |
| FY2023 | $0.71 | -48.4% |
| FY2022 | $1.38 | -12.2% |
| FY2021 | $1.57 | -31.8% |
| FY2020 | $2.31 | +62.4% |
| FY2019 | $1.42 | +3940.7% |
| FY2017 | $0.04 | -0.4% |
| FY2016 | $0.04 | - |
| FY2015 | $0.00 | -100.0% |
As of FY2025 · SEC 10-K · Updated Jun 24, 2026